Jazz Pharmaceuticals plc was named to Fortune magazine’s list of fastest growing companies for 2017. In Fortune‘s annual rankings, Jazz, which makes narcolepsy drug Xyrem, was named the 78th fastest growing company.
“We are honored to be recognized with some of the most innovative companies in the world,” says Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals, in a release. “Our continued growth is a testament to our hard-working, talented employees who are dedicated to bringing innovative therapies to market for life-threatening or complex conditions that have few if any treatment options.”
Fortune magazine’s 100 fastest-growing companies are publicly traded companies ranked by revenue growth rate, EPS growth rate, and 3-year annualized total return for the period ended June 30, 2017. The overall rank is based on the sum of these three ranks.
Jazz—which was recognized by Fortune as the fastest growing company in 2013—is a rapidly growing international biopharmaceutical company that is investing in optimizing the growth of its key products and advancing and expanding its R&D pipeline with a goal of bringing new therapeutic options to patients.
